Elizabeth Douville
Vorstandsvorsitzender bei Insitut de Recherche en Immunologie et en Cancérologie
Profil
Elizabeth Douville is currently the Co-Chief Executive Officer at Insitut de Recherche en Immunologie et en Cancérologie.
She is also the Chairman at Genome Canada, AmorChem Financial, Inc., and holds director positions at LymphoSign, Inc., AgeChem Financial, Inc., Alethia Biotherapeutics, Inc., Corbin Therapeutics, Inc., and Giiant Pharma, Inc. Additionally, she is the General Partner at GeneChem Management, Inc. since 1997.
Dr. Douville previously worked as a Director at Cytochroma, Inc. She obtained her doctorate degree from the University of Ottawa in 1994.
Aktive Positionen von Elizabeth Douville
| Unternehmen | Position | Beginn |
|---|---|---|
GeneChem Management, Inc.
 GeneChem Management, Inc. Investment ManagersFinance GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal. | Private Equity Investor | 01.09.1997 |
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Direktor/Vorstandsmitglied | - |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | - |
Genome Canada
 Genome Canada Miscellaneous Commercial ServicesCommercial Services Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada. | Vorsitzender | - |
AgeChem Financial, Inc.
 AgeChem Financial, Inc. Financial ConglomeratesFinance AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | - |
AmorChem Financial, Inc.
 AmorChem Financial, Inc. Financial ConglomeratesFinance AmorChem Financial, Inc. provides financial investment services. The company is headquartered in Westmount, Canada. | Vorsitzender | - |
Giiant Pharma, Inc.
 Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Direktor/Vorstandsmitglied | - |
Corbin Therapeutics, Inc.
 Corbin Therapeutics, Inc. Internet Software/ServicesTechnology Services Corbin Therapeutics, Inc. operates as a biotechnology platform. | Direktor/Vorstandsmitglied | - |
Insitut de Recherche en Immunologie et en Cancérologie
 Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada. | Vorstandsvorsitzender | 27.02.2023 |
Ehemalige bekannte Positionen von Elizabeth Douville
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Elizabeth Douville
| University of Ottawa | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Cytochroma, Inc.
 Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | Health Technology |
GeneChem Management, Inc.
GeneChem Management, Inc. Investment ManagersFinance GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal. | Finance |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
Genome Canada
Genome Canada Miscellaneous Commercial ServicesCommercial Services Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada. | Commercial Services |
AgeChem Financial, Inc.
AgeChem Financial, Inc. Financial ConglomeratesFinance AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada. | Finance |
AmorChem Financial, Inc.
AmorChem Financial, Inc. Financial ConglomeratesFinance AmorChem Financial, Inc. provides financial investment services. The company is headquartered in Westmount, Canada. | Finance |
Giiant Pharma, Inc.
Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Health Technology |
Corbin Therapeutics, Inc.
Corbin Therapeutics, Inc. Internet Software/ServicesTechnology Services Corbin Therapeutics, Inc. operates as a biotechnology platform. | Technology Services |
Insitut de Recherche en Immunologie et en Cancérologie
Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada. | Commercial Services |
